Biogen Idec - Momentum NASDAQ Founded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. Want More of Our Best Recommendations? |
